
Simone Fishburn 🎗️
@fishburnsimone
Editor in Chief @BioCentury. Dr, the Ph.D-type. Biotech innovation & breaking barriers, one woman at a time. Views are mine, hope to make them yours too.
ID: 470761555
http://linkedin.com/in/simonefishburn 22-01-2012 03:53:19
5,5K Tweet
3,3K Followers
1,1K Following

AZ’s rise in oncology is probably one of biopharma’s all- time top turnaround stories. In this interview with AstraZeneca oncology head Susan Galbraith, we discuss what they did: biocentury.com/article/652988…


In an exclusive conversation with BioCentury, Jim Wilson describes how he plans to use newly launched GemmaBio as a vehicle to create a sustainable model for ultrarare disease gene therapies by capitalizing on efficiencies gained from a platform model. biocentury.com/article/653189



Introducting BioCentury's Back to School 2024. Editor in Chief Simone Fishburn 🎗️ and colleagues drill down on picking the right target, and ask can industry solve its biggest bottleneck? buff.ly/4gieu9K

This Harvard student speaks the truth. “Zionist” is not a slur. Harvard University students need to stop using it as one. The Harvard Crimson thecrimson.com/article/2024/9…

RGC’s Gonçalo Abecasis lent his insights during an enlightening panel discussion at BioCentury Grand Rounds on optimizing data for purpose. He shared that at RGC, “We are big believers that genetic variation leads to good therapies.” #BioCenturyGrandRounds 🧬


BioCentury We’re inspired by Anil Shanker, Ph.D. in his fireside chat about our joint Together for CHANGE initiative to address data and workforce gaps: "This is a dream project to bring together everyone — all pharma, academic partners are invited to join… First we have to build that trust."

John Oyler’s long game at BeiGeneGlobal: Owning the process from clinical trials to manufacturing. The oncology company's CEO sits down with BioCentury Editor in Chief Simone Fishburn 🎗️ to talk company building and what's next for BeiGene buff.ly/3MRnLYR

Our Co-Founder, Chairman and CEO, John V. Oyler, recently joined Simone Fishburn 🎗️ on the BioCentury podcast. They delved into BeiGene's corporate global growth and our innovative pipeline. Tune in to the show to discover more: bit.ly/4ez5BH4


The value in mapping genetics to the medical phenome: case studies from Vanderbilt University. Nancy Cox discusses insights from longitudinal EHRs, biobank data, and their value to drug developers: a BioCentury Q&A buff.ly/3ZDWUaA

I had a fantastic conversation too! John V. Oyler occupies a rare position in biotech of having built a $20B+ company in under 15 years. Some of his lessons, via the podcast (available also on Apple, Spotify and more).





